Chemgenex expands trial to include breast and ovarian cancers
27 September, 2005 by Helen SchullerMelbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has expanded phase II clinical trials of its investigational anti-cancer drug Quinamed to include patients with breast and ovarian cancer.
NeuroSolutions signs $100,000 contract
27 September, 2005 by Ruth BeranUK-based NeuroSolutions, the fully owned subsidiary of neurology-focused biotech NeuroDiscovery (ASX:NDL), is to receive about AUD$100,000 for providing electrophysiology services to drug development company Senexis over the next four months.
Box Hill Institute hires former AusBiotech CEO
27 September, 2005 by Ruth BeranMelbourne TAFE college Box Hill Institute (BHI) has engaged former AusBiotech executive director and CEO Dr Anthony Coulepis to advise on the delivery of education and training through its recently launched BioSkills initiative.
Pharmaxis launches global capital raising
26 September, 2005 by Helen SchullerSydney-based drug developer Pharmaxis (ASX:PXS) has opened a public offering on the sale of ordinary shares in US and a placement of shares in Australia to fund further clinical trials of its lead drugs Bronchitol and Aridol.
US buy boosts Life Therapeutics' plasma business
26 September, 2005 by Helen SchullerSydney-based Life Therapeutics (ASX:LFE) has acquired privately-held California-based Pyramid Biological for US$13 million, plus assumption of US$7 million debt, increasing its stake in the global plasma supply industry.
Epitan founder: why I'm not leaving biotech
26 September, 2005 by Helen SchullerEpitan (ASX:EPT) founder and former managing director and CEO Dr Wayne Millen is set to retire as chairman of the board at the end of October but intends to continue to play a role in the company and the biotech sector.
From A to Z: Amrad wants Zenyth as new name
26 September, 2005 by Ruth BeranMelbourne's Amrad Corporation (ASX:AML) has proposed that its name be changed to Zenyth Therapeutics.
Mesoblast stem cell trial gets ethics approval
23 September, 2005 by Ruth BeranAdult stem cell specialist Mesoblast (ASX:MSB) has received ethics approval to commence its first human orthopaedic trial.
CathRx opens IPO for listing next month
23 September, 2005 by Helen SchullerSydney medical device company CathRx has opened its initial public offering and aims to raise AUD$14 million before listing on the ASX in late October.
New drug discovery facility for Melbourne
22 September, 2005 by Ruth BeranThe privately funded Australian Cancer Research Foundation (ACRF) has awarded a grant of AUD$900,000 to Melbourne's St Vincent's Institute (SVI) to establish a rational drug discovery facility for cancer research.
Vaxine awarded $2.5m bioterrorism grant
21 September, 2005 by Ruth BeranPrivately-held vaccine developer Vaxine and Flinders University have been awarded a grant of US$2.5 million over three years by the US National Institutes of Health (NIH) to develop vaccines that protect against bioterrorist attacks.
Biota aims to raise $10m
21 September, 2005 by Ruth BeranMelbourne-based Biota Holdings (ASX:BTA) is aiming to raise more than AUD$10 million in a non-renounceable share offer to existing shareholders.
Mesoblast to start commercial stem cell production
21 September, 2005 by Ruth BeranMelbourne-based Mesoblast (ASX:MSB) has signed a process development and manufacturing agreement with US life sciences company Cambrex Corporation (NYSE:CMB) for the large scale production of Mesoblast's adult stem cells.
Local pharma firms to distribute Funhaler
21 September, 2005 by Helen SchullerPerth-based biomedical devices developer Visiomed Group (ASX:VSG) has successfully competed negotiations with three pharmaceutical wholesale distributors in Australia for the distribution of its Funhaler incentive asthma spacer into Australian pharmacies.
Ventracor chalks up first revenues
20 September, 2005 by Ruth BeranVentracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.
